RADX

Radiopharm Theranostics Ltd

2.500

-0.120-4.58%

After Hours: 2.560 +0.060 +2.40%16:51 08/19 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.650/2.620

TODAY RANGE2.450-2.708

VOL72.87K

MARKET CAP32.74M

52 WEEK RANGE2.450-16.25

AVG VOL (3M)64.62K

% TURNOVER0.56%

TURNOVER--

P/E (TTM)-0.8143

% RANGE9.86%

EPS(TTM)-3.0701

P/E(FORWARD)-0.8273

P/B0.8548

BVPS2.925

DIVIDEND--

P/S8.26

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP32.74M

SHARES OUTSTANDING13.10M

NEXT EARNINGS--

FREE FLOAT13.10M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

NASDAQ·2d ago
Radiopharm Theranostics To Meet FDA On Phase 3 Design For RAD101; Phase 2b Shows 93% MRI Concordance
TipRanks·2d ago
Radiopharm schedules End-of-Phase 2 meeting with FDA for RAD101
TipRanks·07/28 16:27
Radiopharm Theranostics Secures Multimillion-Dollar Financings to Advance Oncology Radiopharmaceutical Pipeline
TipRanks·07/28 12:28
Radiopharm Theranostics Lists 384 Million New Shares on ASX After ADS Placement
TipRanks·07/27 10:28
Radiopharm Theranostics Launches Multimillion-Dollar U.S. ADS Offering and Australian Equity Raise to Fund Oncology Pipeline
Seeking Alpha·07/24 13:00
Radiopharm Theranostics announces $4.1M registered direct offering and up to A$12.7M Australian financing
TipRanks·07/24 11:30
Radiopharm announces $4.1M registered direct offering
NASDAQ·07/22 15:38
Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204
NASDAQ·07/22 07:57
Radiopharm Reports Positive Phase 2b Data For RAD101 In Brain Metastases Diagnosis
TipRanks·07/22 00:00
Radiopharm Theranostics trading halted, news pending
TipRanks·07/06 11:27
Radiopharm Theranostics Secures A$5.9 Million R&D Tax Refund to Fund Oncology Pipeline
TipRanks·06/04 10:10
Radiopharm initiated with a Buy at H.C. Wainwright
TipRanks·04/20 12:08
Radiopharm announces new data from Phase 0/1 HEAT trial
TipRanks·04/08 12:36
Radiopharm Theranostics Moves HER2 Radiotherapy Candidate RAD202 to Higher Dose in Phase 1 Trial
TipRanks·04/08 11:45
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-0.24%

866.93

Biogen Inc

BIIB

+1.63%

212.55

Amgen Inc

AMGN

-0.63%

415.21

SHPG

CELG-RT

Lilly Eli & Co

LLY

+0.25%

CELG

Therapeuticsmd Inc

TXMD

-0.48%

2.070

Johnson & Johnson

JNJ

+0.78%

262.37

ABBV

Zoetis Inc

ZTS

-2.70%

73.79

Gilead Sciences Inc

GILD

+0.16%

138.36

Novo-Nordisk A/S

NVO

-1.78%

45.89

Bristol-Myers Squibb Co

BMY

-1.27%

63.83

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.30%

26.87

Sanofi FR

SNY

-0.14%

43.72

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-0.55%

150.88

Dr Reddys Labs

RDY

-1.18%

12.13

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.